KEEPsAKE trial 1 (DMARD-IR) and 2 (DMARD/biologic-IR) on risankizumab (IL23i) for PsA: 👉some benefits of risankizumab for axial disease 👉no data regarding bowel disease 👉pts did remain on background DMARDS, steroids. (2/2)